This is a Phase I, FIH, open-label, dose escalation study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed or refractory multiple myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of one infusion of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).
This trial is currently open and accepting patients.
On July 7, 2020, the FDA placed a clinical hold on this clinical trial based on a safety issue in one patient enrolled at the study at dose level two. Learn more
Enrollment: 18 patients (estimated)View More
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
July 07, 2020
Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its MELANI-01 trial.
October 30, 2019
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message